From the perspective of China's healthcare system, the sugemalimab in combination with chemotherapy, regardless of PD-L1 tumor expression level and pathological subtype, was not cost-effective in comparison to chemotherapy as first-line treatment for NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.